JPH04504872A - ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネート - Google Patents
ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネートInfo
- Publication number
- JPH04504872A JPH04504872A JP2506500A JP50650090A JPH04504872A JP H04504872 A JPH04504872 A JP H04504872A JP 2506500 A JP2506500 A JP 2506500A JP 50650090 A JP50650090 A JP 50650090A JP H04504872 A JPH04504872 A JP H04504872A
- Authority
- JP
- Japan
- Prior art keywords
- peg
- group
- formula
- polypeptide
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Abstract
Description
Claims (14)
- 1.式: ▲数式、化学式、表等があります▼ 〔式中、R1はH−、H3C−、N−ジカルボキシイミド基またはその他の任意 の官能基であり; R2、R3及びR4の各々は、直鎖状、分枝状、ジ置換または未置換のアルキル 基であり、R2、R3及びR4の各々は互いに同じ基でもよくまたは夫々に異な る基でもよく;R5はN−ジカルボキシイミド基であり;及びaは1〜1000 の整数、b及びcは夫々0〜1000の整数であり、aとbとcとの和が10〜 1000である〕で示される構造を有する化合物。
- 2.R2、R3及びR4の各々が、CH2CH2、CH2CHCH3またはCH 2CH2CH2CH2であることを特徴とする請求項1に記載の化合物。
- 3.R1及びR5の各々が、N−スクシンイミド、N−フタルイミド、N−グル タルイミド、N−テトラヒドロフタルイミド及びN−ノルボルネン−2,3−ジ カルボキシイミドから成るグループから選択されたN−ジカルボキシイミド基で あり、R1及びR5が同じ基であっても異なる基であってもよいことを特徴とす る請求項1に記載の化合物。
- 4.R5がN−スクシンイミド基であることを特徴とする請求項3に記載の化合 物。
- 5.式: ▲数式、化学式、表等があります▼ 〔式中、R1はH3C−、H−、N−ジカルボキシイミド基またはその他の任意 の官能基;aは10〜1000の整数である〕で示される構造を有する請求項1 に記載の化合物。
- 6.式: ▲数式、化学式、表等があります▼ 〔式中、aは10〜1000の整数である〕で示される構造を有する請求項1に 記載の化合物。
- 7.式: ▲数式、化学式、表等があります▼ 〔式中、R1はH−、H3C−、N−ジカルボキシイミド基またはその他の任意 の官能基であり; R2、R3及びR4の各々は直鎖状、分枝状、ジ置換または未置換のアルキル基 であり、R2、R3及びR4の各々は互いに同じ基でもよく夫々に異なる基でも よく;Xはハロゲンであり; aは1〜1000の整数、b及びcは夫々0〜1000の整数であり、aとbと cとの和が10〜1000である〕で示される構造を有する化合物と、N−ヒド ロキシジカルボキシイミドとを塩基の存在下に反応させることを特徴とする請求 項1に記載の化合物の製造方法。
- 8.N−ヒドロキシジカルボキシイミドがN−ヒドロキシスクシンイミドである ことを特徴とする請求項7に記載の方法。
- 9.ハロゲンが塩素であり、塩基がトリエチルアミンであることを特徴とする請 求項7に記載の方法。
- 10.式: ▲数式、化学式、表等があります▼ 〔式中、R1はH−、H3C−またはN−ジカルボキシイミド基またはその他の 任意の官能基であり;R2、R3及びR4の各々は直鎖状、分枝状、置換または 未置換のアルキル基であり、R2、R3及びR4の各々は互いに同じ基でもよく または異なる基でもよく;aは1〜1000の整数、b及びcは夫々0〜100 0の整数であり、aとbとcとの和が10〜1000である〕で示される構造を 有する少なくとも1種のポリマーと結合したポリペプチドを含み、各ポリマーが ウレタン結合によってポリペプチドのアミン基に共有結合していることを特徴と する修飾ポリペプチド。
- 11.式 ▲数式、化学式、表等があります▼ポリペプチドで示される構造を有する請求項 1に記載の修飾ポリペプチド。
- 12.ポリペプチドがウシ血清アルブミン、グルタミナーゼ、トリプシン、アル ギナーゼ、キモトリプシン、アスパラギナーゼまたはアデノシンデアミナーゼで あることを特徴とする請求項12に記載の修飾ポリペプチド。
- 13.約5.8〜11のpHでポリペプチドを請求項1の化合物と反応させるこ とを特徴とする修飾ポリペプチドの製造方法。
- 14.pHが約9.3であることを特徴とする請求項12に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34092889A | 1989-04-19 | 1989-04-19 | |
US340,928 | 1989-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04504872A true JPH04504872A (ja) | 1992-08-27 |
JP2875884B2 JP2875884B2 (ja) | 1999-03-31 |
Family
ID=23335516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2506500A Expired - Lifetime JP2875884B2 (ja) | 1989-04-19 | 1990-04-19 | ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネート |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0893439B1 (ja) |
JP (1) | JP2875884B2 (ja) |
AT (2) | ATE181732T1 (ja) |
AU (1) | AU5526690A (ja) |
CA (1) | CA2053317C (ja) |
DE (2) | DE69034200T2 (ja) |
DK (2) | DK0893439T3 (ja) |
ES (2) | ES2247656T3 (ja) |
HU (1) | HUT64022A (ja) |
WO (1) | WO1990013540A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003206236A (ja) * | 1993-05-10 | 2003-07-22 | Nobex Corp | 接合安定化されたポリペプチド組成物 |
JP2007516302A (ja) * | 2003-06-20 | 2007-06-21 | ワーウィック イフェクト ポリマーズ リミテッド | ポリペプチド等と反応し得る官能基を含むリビングラジカル重合開始剤、それを用いて得られる櫛形ポリマー、それから得られるポリペプチド複合体及び薬剤 |
JP2008530271A (ja) * | 2005-02-04 | 2008-08-07 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポリマー複合体の調製方法 |
JP2011528032A (ja) * | 2008-07-14 | 2011-11-10 | バイオコン リミテッド | 実質的に単分散のオリゴマー混合物の合成方法 |
JP2019521179A (ja) * | 2016-06-01 | 2019-07-25 | セルヴィエ アイピー ユーケー リミテッド | ポリアルキレンオキシド−アスパラギナーゼの製剤ならびにその製造法および使用法 |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0576589A4 (en) * | 1991-03-18 | 1994-07-27 | Enzon Inc | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
GB9116610D0 (en) * | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
CA2101361A1 (en) * | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5583114A (en) * | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
WO1996040792A1 (en) * | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
AU5893696A (en) * | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
AR027509A1 (es) | 2000-01-10 | 2003-04-02 | Maxygen Aps | Conjugados g-csf |
RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
US6576263B2 (en) | 2000-02-17 | 2003-06-10 | 3M Innovative Properties Company | Delivery systems using preformed biodegradable polymer compositions and methods |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
EP2080771A3 (en) | 2001-02-27 | 2010-01-06 | Maxygen Aps | New interferon beta-like molecules |
PT2279753E (pt) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodelação e glicoconjugação de péptidos |
EP2305311A3 (en) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
DK1499719T3 (da) | 2002-04-30 | 2011-02-28 | Bayer Healthcare Llc | Faktor VII- eller VIIa-polypeptidvarianter |
UA86744C2 (en) | 2002-06-21 | 2009-05-25 | Ново Нордиск Хэлс Кеа Аг | Pegylated factor vii glycoforms |
EP1616003A4 (en) | 2002-12-30 | 2007-06-20 | Gryphon Therapeutics Inc | WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
EP1608688B1 (en) | 2003-03-14 | 2013-02-27 | BioGeneriX AG | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
AU2004240553A1 (en) | 2003-05-09 | 2004-12-02 | Neose Technologies, Inc. | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
ATE481420T1 (de) | 2003-10-10 | 2010-10-15 | Novo Nordisk As | Il-21-derivate |
ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
KR20070010175A (ko) * | 2004-04-21 | 2007-01-22 | 알자 코포레이션 | 온화한 가티올분해 조건하에서 방출될 수 있는 폴리머콘쥬게이트 |
CN1997401A (zh) | 2004-06-08 | 2007-07-11 | 阿尔扎公司 | 通过四组分的缩合反应来制备大分子共轭物 |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
NZ555206A (en) | 2004-12-22 | 2010-09-30 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
AU2005319518B2 (en) | 2004-12-22 | 2010-09-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
WO2006074467A2 (en) | 2005-01-10 | 2006-07-13 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
CA2602654A1 (en) | 2005-04-05 | 2006-10-12 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for shielding functional sites or epitopes on proteins |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
US20100135959A1 (en) | 2005-06-03 | 2010-06-03 | Ambrx, Inc. | Human Interferon Molecules and Their Uses |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
EP2339014B1 (en) | 2005-11-16 | 2015-05-27 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP1797901A1 (en) | 2005-12-16 | 2007-06-20 | Diatos | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
KR101201055B1 (ko) | 2006-03-13 | 2012-11-15 | 리아트 민쯔 | 악액질 및/또는 식욕감퇴 및/또는 식욕감퇴-악액질 및/또는영양장애 및/또는 지방이영양증 및/또는 근육 쇠약 및/또는 식욕-자극의 치료를 위한 그렐린 스플라이스 변이체의 용도 |
EP2029738A2 (en) | 2006-05-24 | 2009-03-04 | Novo Nordisk Health Care AG | Factor ix analogues having prolonged in vivo half life |
EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
MX2009002460A (es) | 2006-09-08 | 2009-03-20 | Ambrx Inc | Arnt supresor hibrido para celulas de vertebrados. |
EP2615108B1 (en) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and thier uses |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
DK2068907T3 (en) | 2006-10-04 | 2018-01-15 | Novo Nordisk As | GLYCEROL BOND PEGYLED SUGAR AND GLYCOPE Peptides |
ES2385114T3 (es) | 2007-03-30 | 2012-07-18 | Ambrx, Inc. | Polipéptidos de FGF-21 modificados y sus usos |
CN101796063B (zh) | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | 使用糖聚乙二醇化g‑csf的治疗方法 |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2170919B8 (en) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
NZ603812A (en) | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
CN101939443B (zh) | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
UA103774C2 (uk) | 2008-07-23 | 2013-11-25 | Амбркс, Інк. | Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування |
DK2337846T3 (en) | 2008-09-26 | 2018-03-12 | Ambrx Inc | NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES |
WO2010036964A2 (en) | 2008-09-26 | 2010-04-01 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
KR102210133B1 (ko) | 2009-06-09 | 2021-02-01 | 프로롱 파마슈티컬스, 엘엘씨 | 헤모글로빈 조성물 |
NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
CN102666578A (zh) | 2009-12-21 | 2012-09-12 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
AU2011222883B2 (en) | 2010-03-05 | 2016-05-26 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Vla4のポリペプチド阻害剤 |
KR101963460B1 (ko) | 2010-08-17 | 2019-03-28 | 암브룩스, 인코포레이티드 | 변형된 릴랙신 폴리펩타이드 및 그것의 용도 |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
RU2013142015A (ru) | 2011-03-02 | 2015-04-10 | Ново Нордиск А/С | Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов |
EP2721057B1 (en) | 2011-06-15 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer |
RU2014103288A (ru) | 2011-07-01 | 2015-08-10 | Байер Интеллектчуал Проперти Гмбх | Слитые полипептиды релаксина и их применение |
AU2012278944B2 (en) | 2011-07-05 | 2015-09-17 | Bioasis Technologies Inc. | p97-antibody conjugates and methods of use |
BR112014026442A8 (pt) | 2012-05-01 | 2018-01-16 | Novo Nordisk As | combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica. |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
CN104662150B (zh) | 2012-07-31 | 2018-07-10 | 比奥阿赛斯技术有限公司 | 脱磷酸化的溶酶体贮积症蛋白及其使用方法 |
KR102182800B1 (ko) | 2012-08-31 | 2020-11-25 | 서트로 바이오파마, 인크. | 아지도 기를 포함하는 변형된 아미노산 |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
CN104870423A (zh) | 2012-11-16 | 2015-08-26 | 加利福尼亚大学董事会 | 用于蛋白质化学修饰的pictet-spengler连接反应 |
AU2014243816B2 (en) | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
JP6586016B2 (ja) | 2013-03-15 | 2019-10-02 | ノヴォ ノルディスク アー/エス | 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体 |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
CN115504924A (zh) | 2013-11-27 | 2022-12-23 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
ES2874331T3 (es) | 2014-10-24 | 2021-11-04 | Bristol Myers Squibb Co | Polipéptidos de FGF-21 modificados y usos de los mismos |
WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
EP3529615A1 (en) | 2016-10-24 | 2019-08-28 | Novo Nordisk A/S | Bioassay for insulin formulations |
MY193457A (en) | 2017-02-08 | 2022-10-14 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
WO2019038420A1 (en) | 2017-08-25 | 2019-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES |
WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
CN112384573A (zh) | 2018-03-30 | 2021-02-19 | 贝克顿·迪金森公司 | 含侧基发色团的水溶性聚合染料 |
WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
HRP20240016T1 (hr) | 2018-09-11 | 2024-03-29 | Ambrx, Inc. | Konjugati polipeptida interleukina-2 i njihove uporabe |
WO2020089743A1 (en) | 2018-11-02 | 2020-05-07 | Cadila Healthcare Limited | Pharmaceutical composition of pegylated l-asparaginase |
WO2021048171A1 (en) | 2019-09-10 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to improve phagocytosis |
EP4117732A1 (en) | 2020-03-11 | 2023-01-18 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
CN116744984A (zh) | 2020-12-28 | 2023-09-12 | 达沃有限公司 | 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料 |
WO2022152698A1 (en) | 2021-01-12 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of npdk-d to evaluate cancer prognosis |
WO2022200469A1 (en) | 2021-03-24 | 2022-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A dominant negative protein of rad51 for treating cancer |
EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2631656C2 (de) * | 1976-07-14 | 1983-02-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe |
CS204190B1 (en) † | 1978-02-22 | 1981-03-31 | Jaroslav Drobnik | Activation method for hydrxyl groups containing insoluble carriers |
DD219490A1 (de) † | 1983-10-28 | 1985-03-06 | Akad Wissenschaften Ddr | Verfahren zur herstellung aktivierter traeger |
YU144584A (en) † | 1983-08-25 | 1987-06-30 | Akad Wissenschaften Ddr | Process for making n-(chlorocarbonyloxi)-s-norbornen-2,3-dicarboximide |
JPS60156395A (ja) * | 1984-01-17 | 1985-08-16 | Mihama Hisaharu | 修飾リパーゼ |
DE3413904A1 (de) * | 1984-04-13 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen, verfahren zu ihrer herstellung und ihre anwendung |
FR2574075B1 (fr) * | 1984-12-04 | 1987-09-18 | Poudres & Explosifs Ste Nale | Procede de synthese d'esters actifs d'acides carboxyliques, nouveaux carbonates alpha-halogenes utiles pour cette synthese et leur mode d'obtention |
JPH0757760B2 (ja) * | 1987-06-05 | 1995-06-21 | 宇部興産株式会社 | 生体由来物質の固定化方法 |
DD261791A1 (de) † | 1987-06-30 | 1988-11-09 | Akad Wissenschaften Ddr | Verfahren zur herstellung von carbonaten hydroxylgruppenhaltiger polymere |
DD260701A1 (de) † | 1987-06-30 | 1988-10-05 | Akad Wissenschaften Ddr | Verfahren zur umesterung von aktiven unsymmetrischen kohlensaeurediester-gruppen an hydroxylgruppenhaltigen polymeren |
IE64284B1 (en) † | 1987-08-03 | 1995-07-26 | Ddi Pharmaceuticals | Conjugates of superoxide dismutase |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
-
1990
- 1990-04-19 CA CA002053317A patent/CA2053317C/en not_active Expired - Lifetime
- 1990-04-19 WO PCT/US1990/002133 patent/WO1990013540A1/en active IP Right Grant
- 1990-04-19 JP JP2506500A patent/JP2875884B2/ja not_active Expired - Lifetime
- 1990-04-19 AT AT90906698T patent/ATE181732T1/de not_active IP Right Cessation
- 1990-04-19 DE DE69034200T patent/DE69034200T2/de not_active Expired - Lifetime
- 1990-04-19 EP EP98203166A patent/EP0893439B1/en not_active Expired - Lifetime
- 1990-04-19 ES ES98203166T patent/ES2247656T3/es not_active Expired - Lifetime
- 1990-04-19 AU AU55266/90A patent/AU5526690A/en not_active Abandoned
- 1990-04-19 DK DK98203166T patent/DK0893439T3/da active
- 1990-04-19 ES ES90906698T patent/ES2136595T5/es not_active Expired - Lifetime
- 1990-04-19 HU HU903628A patent/HUT64022A/hu unknown
- 1990-04-19 AT AT98203166T patent/ATE300519T1/de not_active IP Right Cessation
- 1990-04-19 EP EP90906698A patent/EP0470128B2/en not_active Expired - Lifetime
- 1990-04-19 DE DE69033192T patent/DE69033192T3/de not_active Expired - Lifetime
- 1990-04-19 DK DK90906698T patent/DK0470128T4/da active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003206236A (ja) * | 1993-05-10 | 2003-07-22 | Nobex Corp | 接合安定化されたポリペプチド組成物 |
JP2007516302A (ja) * | 2003-06-20 | 2007-06-21 | ワーウィック イフェクト ポリマーズ リミテッド | ポリペプチド等と反応し得る官能基を含むリビングラジカル重合開始剤、それを用いて得られる櫛形ポリマー、それから得られるポリペプチド複合体及び薬剤 |
JP2008530271A (ja) * | 2005-02-04 | 2008-08-07 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポリマー複合体の調製方法 |
JP2011528032A (ja) * | 2008-07-14 | 2011-11-10 | バイオコン リミテッド | 実質的に単分散のオリゴマー混合物の合成方法 |
JP2019521179A (ja) * | 2016-06-01 | 2019-07-25 | セルヴィエ アイピー ユーケー リミテッド | ポリアルキレンオキシド−アスパラギナーゼの製剤ならびにその製造法および使用法 |
Also Published As
Publication number | Publication date |
---|---|
DK0470128T3 (da) | 2000-01-10 |
WO1990013540A1 (en) | 1990-11-15 |
DE69034200T2 (de) | 2006-05-24 |
ATE181732T1 (de) | 1999-07-15 |
ES2136595T3 (es) | 1999-12-01 |
EP0470128A1 (en) | 1992-02-12 |
ES2136595T5 (es) | 2004-04-01 |
ES2247656T3 (es) | 2006-03-01 |
JP2875884B2 (ja) | 1999-03-31 |
CA2053317C (en) | 1996-03-12 |
EP0470128B1 (en) | 1999-06-30 |
EP0470128A4 (en) | 1992-09-16 |
EP0893439A1 (en) | 1999-01-27 |
EP0470128B2 (en) | 2003-08-13 |
DE69033192T2 (de) | 2000-03-09 |
DK0470128T4 (da) | 2003-12-01 |
EP0893439B1 (en) | 2005-07-27 |
DK0893439T3 (da) | 2005-09-05 |
HU903628D0 (en) | 1991-12-30 |
AU5526690A (en) | 1990-11-29 |
DE69033192T3 (de) | 2004-05-19 |
DE69033192D1 (de) | 1999-08-05 |
DE69034200D1 (de) | 2005-09-01 |
CA2053317A1 (en) | 1990-10-20 |
ATE300519T1 (de) | 2005-08-15 |
HUT64022A (en) | 1993-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH04504872A (ja) | ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネート | |
US5808096A (en) | Process for preparing active carbonates of polyalkylene oxides for modification of polypeptides | |
US5612460A (en) | Active carbonates of polyalkylene oxides for modification of polypeptides | |
JP3342060B2 (ja) | Pegイミデート類およびそれらの蛋白質誘導体 | |
AU764144B2 (en) | Polyamide chains of precise length, methods to manufacture them and their conjugates | |
CA2631335C (en) | Four branched dendrimer-peg for conjugation to proteins and peptides | |
EP0200467B1 (en) | Superoxide dismutase combined with a poly(alkylene oxide) | |
US8465734B2 (en) | Methods for increasing protein polyethylene glycol (PEG) conjugation | |
Boccu et al. | Coupling of monomethoxypolyethyleneglycols to proteins via active esters | |
KR20060136463A (ko) | 폴리에틸렌 글리콜(peg) 단백질 결합을 증가시키기 위한방법 | |
EP0632082B1 (en) | Preparation of activated carbamates of poly(alkylene glycol) and their use | |
US6737524B2 (en) | Activated polyethylene glycol compounds | |
Nijs et al. | Acylation of amino functions of proteins with monomethoxypoly (ethylene glycol)-N-succinimide carbonate | |
JP2657694B2 (ja) | 化学修飾酵素ならびにペプチド合成方法 | |
Naturforsch | Coupling of Monomethoxypolyethyleneglycols to Proteins via Active Esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090114 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090114 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100114 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110114 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110114 Year of fee payment: 12 |